2023 World Conference on Lung Cancer (Posters)-EP10.01. Sarcopenia as a Predictive Factor of Carboplatin Toxicity in Patients with Advanced Non-small Cell Lung Cancer

EP10.01. Sarcopenia as a Predictive Factor of Carboplatin Toxicity in Patients with Advanced Non-small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

A study presented at the WCLC 2023 conference investigated the association between sarcopenia and carboplatin toxicity in patients with advanced non-small cell lung cancer (NSCLC). Carboplatin is a commonly used chemotherapy drug in NSCLC, and it is typically dosed based on body weight, which does not account for the presence of sarcopenia. Sarcopenia refers to the loss of skeletal muscle mass and is known to have a negative impact on cancer outcomes.<br /><br />The study analyzed the toxicity related to the first two cycles of carboplatin-based treatment in 146 patients with locally advanced or metastatic NSCLC. Sarcopenia was determined based on the skeletal muscle area at the axial level of the third lumbar vertebral using computed tomography. The prevalence of sarcopenia before treatment was found to be 52%.<br /><br />The results showed that sarcopenia was significantly associated with hematological toxicity, as all patients with hematological toxicity had sarcopenia. Factors such as age over 60, clinical stage IV, low skeletal muscle index (SMI), and low subcutaneous adipose tissue index (SATI) were independently associated with hematological toxicity.<br /><br />Dose-limiting toxicity (DLT) was registered in 27.3% of patients, and clinical stage IV and low SMI were independently associated with DLT. The study also observed significant variations in the dose estimations and dose received of carboplatin based on creatinine clearance equations.<br /><br />In conclusion, the study found that sarcopenia was a predictive factor for carboplatin toxicity in patients with advanced NSCLC. The findings highlight the importance of considering sarcopenia in the dosing of chemotherapy drugs to improve treatment outcomes.

Asset Subtitle

Jenny Turcott

Meta Tag

Speaker Jenny Turcott

Topic Metastatic NSCLC: Cytotoxic Therapy

Keywords

sarcopenia

carboplatin toxicity

non-small cell lung cancer

NSCLC

chemotherapy drug

body weight

skeletal muscle mass

cancer outcomes

hematological toxicity

dose-limiting toxicity